Dr. Martens’ (DOCS) Sector perform Rating Reaffirmed at Royal Bank Of Canada

Royal Bank Of Canada restated their sector perform rating on shares of Dr. Martens (LON:DOCS) in a report issued on Tuesday, Marketbeat reports.

A number of other equities research analysts also recently commented on DOCS. Berenberg Bank reissued a “buy” rating on shares of Dr. Martens in a research report on Tuesday, January 27th. Peel Hunt reaffirmed a “buy” rating on shares of Dr. Martens in a research report on Thursday, November 20th. Two research analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of GBX 6,000.

Dr. Martens Price Performance

DOCS stock opened at GBX 65.60 on Tuesday. The business’s 50-day moving average is GBX 75.38 and its two-hundred day moving average is GBX 82.96. The company has a debt-to-equity ratio of 127.27, a current ratio of 2.85 and a quick ratio of 1.13. The firm has a market capitalization of £634.06 million, a P/E ratio of 38.59, a P/E/G ratio of 6.40 and a beta of 0.11. Dr. Martens has a 1 year low of GBX 43.02 and a 1 year high of GBX 100.87.

Dr. Martens (LON:DOCS) last released its earnings results on Thursday, November 20th. The company reported GBX (0.90) earnings per share for the quarter. Dr. Martens had a return on equity of 18.91% and a net margin of 7.89%. Analysts anticipate that Dr. Martens will post 2.5809394 earnings per share for the current fiscal year.

Insider Buying and Selling at Dr. Martens

In related news, insider Robert Hanson bought 96,000 shares of the stock in a transaction dated Friday, December 5th. The stock was acquired at an average price of GBX 79 per share, for a total transaction of £75,840. In the last ninety days, insiders have purchased 97,130 shares of company stock worth $7,673,816. 2.79% of the stock is currently owned by insiders.

Dr. Martens Company Profile

Founded in 1960, Dr. Martens is an iconic British brand with a global presence. “Docs” or “DMs” were originally
produced for their durability for workers, before being adopted by diverse youth subcultures and associated musical
movements. Today, Dr. Martens has transcended its roots while still celebrating its proud history. It operates in over
60 countries and employs over 3,650 people worldwide. Its operations are split across both Direct-to-Consumer and
wholesale channels, and in addition to its world-renowned “1460” boot its product segments span shoes including the
1461 shoe and Adrian loafer, sandals including the Zebzag mule, Kids ranges, as well as a growing line of bags and
accessories.

The Company successfully listed on the main market of the London Stock Exchange on 29 January 2021 (DOCS.L) and
is a constituent of the FTSE 250 index.